PDGFRB and gastrointestinal stromal tumor: Activating mutations within the KIT gene and, to a lesser degree, PDGFR, are commonly found in patients with GIST and depending on their location within the coding region of the respective gene, they are highly correlated with the likelihood of a response to imatinib mesylate treatment (44, 45).